News
18m
Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease
Extension of the Phase 1b study will allow participants to continue dosing with GT-02287 for an additional nine months after completing the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback